Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LocusTau: Locus coeruleus biomarkers, early tau pathology and cognition in AD risk
2023-507668-38-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of flortaucipir in Alzheimer's disease (AD) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary diagnostic performance of LC biomarkers for tau PET positivity. Planned start Nov 2024; status: authorised.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-507668-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507668-38-00.